Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Interventions: SAGE-718, SAGE-718-matching Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 37
States / cities: Gilbert, Arizona • Phoenix, Arizona • Lafayette, California + 34 more

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Gefapixant, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 4
States / cities: Hallandale, Florida • Hollywood, Florida • Atlanta, Georgia + 1 more

Conditions: Respiratory Syncytial Virus
Interventions: EDP-938, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Pelham, Alabama • Anaheim, California + 9 more

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 8
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more

Conditions: Intraventricular Hemorrhage, Periventricular Leukomalacia, Brain Injury, Renal Injury
Interventions: Indomethacin, delay in umbilical cord clamp at birth, placebo infusion, immediate cord clamp at birth; Drug · Procedure
Lead sponsor: Hong Huang; Other
Eligibility: 24 Weeks to 30 Weeks
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, Abiraterone acetate, Prednisone, Placebo; Drug
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 982 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 46
States / cities: Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more

Conditions: Healthy Volunteers
Interventions: AZD1163, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin, Sitagliptin, Placebo for sitagliptin, Placebo for bexagliflozin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Lincoln, California • Long Beach, California • San Dimas, California + 7 more

Conditions: Schizophrenia, Cigarette Smoking
Interventions: Varenicline, Placebo for varenicline; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: New York, New York • Orangeburg, New York

Conditions: Psoriasis, Plaque Psoriasis
Interventions: MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant 150 mg, Ketoconazole, Casopitant 150 mg matching placebo, Casopitant 50 mg, Casopitant 50 mg matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 3
States / cities: Overland Park, Kansas • Buffalo, New York • Columbus, Ohio

Conditions: Asthma, Allergic
Interventions: REGN3500, Dupilumab, Placebo, Fluticasone propionate; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Schwannomatosis, Pain
Interventions: Tanezumab, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: Placebo, RO4917838, Antipshychotics (Standard of Care); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 27
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more

Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions: ExPEC9V, Placebo; Biological · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 60 Years and older
Enrollment: 17,797 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 142
States / cities: Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more

Conditions: Platysma Prominence
Interventions: NT 201, NT 201 Placebo; Drug
Lead sponsor: Merz Aesthetics GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Aventura, Florida • Coral Gables, Florida + 3 more

Conditions: Alzheimer's Disease
Interventions: RO7568282, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Stuart, Florida • Wellington, Florida • Winter Park, Florida + 1 more

Conditions: Essential Tremor
Interventions: SAGE-324, SAGE-324 Matched Placebo; Drug
Lead sponsor: Sage Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 51
States / cities: Hoover, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more

Conditions: Cystic Fibrosis
Interventions: VX-152, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more

Conditions: Hidradenitis Suppurativa
Interventions: PTM-001, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Redwood City, California • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Crohn Disease
Interventions: Etrolizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 62
States / cities: Arcadia, California • La Jolla, California • Long Beach, California + 53 more

Search by objective public record fields.

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults

Study of REGN3500 and Dupilumab in Patients With Asthma

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

A Study of NT 201 Doses in the Treatment of Platysma Prominence

Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

Study to Evaluate SAGE-324 in Participants With Essential Tremor

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease